BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 19733167)

  • 1. Platelet linoleic acid is a potential biomarker of advanced non-small cell lung cancer.
    de Castro J; Rodríguez MC; Martínez-Zorzano VS; Llanillo M; Sánchez-Yagüe J
    Exp Mol Pathol; 2009 Dec; 87(3):226-33. PubMed ID: 19733167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1.
    de Castro J; Rodríguez MC; Martínez-Zorzano VS; Hernández-Hernández A; Llanillo M; Sánchez-Yagüe J
    Cancer Invest; 2008 May; 26(4):407-18. PubMed ID: 18443962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrocyte fatty acids as potential biomarkers in the diagnosis of advanced lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer.
    de Castro J; Rodríguez MC; Martínez-Zorzano VS; Sánchez-Rodríguez P; Sánchez-Yagüe J
    Am J Clin Pathol; 2014 Jul; 142(1):111-20. PubMed ID: 24926094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma.
    De Castro J; Hernández-Hernández A; Rodríguez MC; Sardina JL; Llanillo M; Sánchez-Yagüe J
    Platelets; 2007 Feb; 18(1):43-51. PubMed ID: 17365853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of changes in erythrocyte and platelet fatty acid composition and protein oxidation in advanced non-small cell lung cancer.
    de Castro J; Hernández-Hernández A; Rodríguez MC; Llanillo M; Sánchez-Yagüe J
    Cancer Invest; 2006; 24(4):339-45. PubMed ID: 16777684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of occurrence frequency of circulating p53 protein in serum of patients with chronic obstructive pulmonary diseases and non-small cell lung cancer].
    Targowski T; Janda P; Owczarek W; Raczka A; Jahnz-Rózyk K; Płusa T
    Pol Merkur Lekarski; 2010 Apr; 28(166):265-7. PubMed ID: 20491334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
    Planque C; Li L; Zheng Y; Soosaipillai A; Reckamp K; Chia D; Diamandis EP; Goodglick L
    Clin Cancer Res; 2008 Mar; 14(5):1355-62. PubMed ID: 18316555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Identification and clinical evaluation of lung cancer serum biomarker L-lactate dehydrogenase B].
    Chen Y; Zhang H; Xu AJ; Liu JF; Li N; Wu SS; Huang LY; He DC; Xiao XY
    Zhonghua Jie He He Hu Xi Za Zhi; 2007 Aug; 30(8):577-81. PubMed ID: 17988549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated changes of platelet ultra microstructure and plasma granule membrane protein 140 in patients with non-small cell lung cancer.
    Zhuge Y; Zhou JY; Yang GD; Zu DL; Xu XL; Tian MQ; Lu GH
    Chin Med J (Engl); 2009 May; 122(9):1026-31. PubMed ID: 19493436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of potential erythrocyte phospholipid fatty acid biomarkers of advanced lung adenocarcinoma, squamous cell lung carcinoma, and small cell lung cancer.
    Sánchez-Rodríguez P; Rodríguez MC; Sánchez-Yagüe J
    Tumour Biol; 2015 Jul; 36(7):5687-98. PubMed ID: 25702090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the cut-off value of pro-gastrin releasing peptide (ProGRP) in lung cancer according to population characteristics.
    Bubanović G; Pavićević R; Franjević A
    Coll Antropol; 2008 Dec; 32(4):1155-64. PubMed ID: 19149223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer.
    Barak V; Holdenrieder S; Nisman B; Stieber P
    Cancer Biomark; 2010; 6(3-4):191-6. PubMed ID: 20660964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the differential from complete blood counts as a biomarker of fatigue in advanced non-small-cell lung cancer: an exploratory analysis.
    Paddison JS; Temel JS; Fricchione GL; Pirl WF
    Palliat Support Care; 2009 Jun; 7(2):213-7. PubMed ID: 19538804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYFRA 21-1 in non-small cell lung cancer--standardisation and application during diagnosis.
    Pavićević R; Bubanović G; Franjević A; Stancić-Rokotov D; Samarzija M
    Coll Antropol; 2008 Jun; 32(2):485-98. PubMed ID: 18756899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Membrane platelet fatty acids: biochemical characterisation of the ischemic cardiovascular disease, characteristics of the paediatric age, through an artificial neural network interpretation].
    Cocchi M; Tonello L; Cappello G; Tarozzi G; Nabacino L; Pastorini E; Bucciarelli S; Solazzo L; De Luca M; Visci G; Caramia G
    Pediatr Med Chir; 2008; 30(1):25-30. PubMed ID: 18491675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD.
    Dragonieri S; Annema JT; Schot R; van der Schee MP; Spanevello A; Carratú P; Resta O; Rabe KF; Sterk PJ
    Lung Cancer; 2009 May; 64(2):166-70. PubMed ID: 18834643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life in end-stage COPD and lung cancer patients.
    Habraken JM; ter Riet G; Gore JM; Greenstone MA; Weersink EJ; Bindels PJ; Willems DL
    J Pain Symptom Manage; 2009 Jun; 37(6):973-81. PubMed ID: 19394792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.
    Hoffmann AC; Kaifi JT; Vallböhmer D; Yekebas E; Grimminger P; Leers JM; Izbicki JR; Hölscher AH; Schneider PM; Metzger R; Brabender J
    J Surg Oncol; 2009 Oct; 100(5):414-7. PubMed ID: 19653236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry.
    Wu H; Xue R; Lu C; Deng C; Liu T; Zeng H; Wang Q; Shen X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Oct; 877(27):3111-7. PubMed ID: 19716777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.